Product nameRecombinant EBV p23 protein
This protein is immunoreactive with sera of EBV-infected individuals.
Purity> 95 % SDS-PAGE.
Sepharose-Derived Purification determined by 10% PAGE (coomassie staining).
Expression systemEscherichia coli
Protein lengthFull length protein
Our Abpromise guarantee covers the use of ab43145 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at Room Temperature. Store at -20°C.
Constituents: 0.1875% Glycine, 50% Glycerol
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- Epstein Barr virus p23 protein
- HHV4 p23
RelevanceThe Epstein Barr virus (EBV) is a human herpes virus 4 (HHV4) that infects and establishes latency in B-lymphocytes. Primary infection leads to a life-long past infection which is normally asymptomatic. EBV expresses a number of genes, however, Epstein Barr nuclear antigen 1 (EBNA1) p72 is the only viral protein which characterizes EBV past-infection. p23 is one of the two small viral capsid antigens (VCA). EBV p23 is a viral late complex associated with virion particles and consists of two gene products, BFRF3 and BLRF2. EBV has a worldwide distribution, with over 90% of the adult population showing evidence of past infection. The virus, acquired during childhood, usually causes no symptoms. However, in Western societies, 10 to 20% of adolescents and young adults develop acute infectious mononucleosis (IM). In humans, EBV is also associated with cancer, in particular Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, and immunoblastic lymphoma.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab43145 has not yet been referenced specifically in any publications.